Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions

Table 2

Summary of current strategies being investigated in mismatch repair-deficient microsatellite instability-high colorectal cancers.

Current strategies	Agent (s)	Target (s)	FDA approval Date
Single-agent ICIs	Tremelimumab [143]	CTLA-4	.....
	Nivolumab [144, 146–148]	PD-1	July 2017
	Pembrolizumab [42, 134]		May 2017
	Atezolizumab [10, 43]	PD-L1	.....
	Avelumab [10, 43]		.....
	Durvalumab [10, 43]		.....
ICI + chemotherapy	Bevacizumab + FOLFOX [152]	VEGF for Bevacizumab	.....
	Atezolizumab + FOLFOX [13, 153, 154]	PD-L1 for Atezolizumab	.....
Combinations of ICIs	Durvalumab + Tremelimumab [157, 158]	PD-L1 + CTLA-4, respectively	.....
	Nivolumab + Ipilimumab [147, 159]	PD-1 + CTLA-4, respectively	July 2018